Clinical Trials Search Results

  • Resize font
  • Print
  • Email
  • Facebook
  • Twitter
  • Google+
  • Pinterest

Initial search results include only NCI-sponsored clinical trials. To search all trials, click the "REFINE SEARCH" button, scroll down to the Trial ID/Sponsor section and select the "All" check box in the Sponsor of Trial section.

View Content for:
Display:
?
Drug:  axitinib
Find trials that include:  Any drugs shown
Trial Status:  Active
Results 1-22 of 22 for your search:
Start Over
Post Marketing Surveillance Study to Observe Safety and Efficacy of Inlyta in South Korea
Phase: Phase IV
Type: Natural history/Epidemiology
Status: Approved-not yet active
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: A4061075, NCT02156895
Adjuvant Axitinib Therapy of Renal Cell Cancer in High Risk Patients
Phase: Phase III
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: AP311736, NCT01599754
Axitinib in Malignant Mesothelioma
Phase: Phase II, Phase I
Type: Biomarker/Laboratory analysis, Treatment
Status: Active
Age: 18 and over
Sponsor: Other
Protocol IDs: NL25655.031.08, NCT01211275
A Randomized Phase 2 Trial of Axitinib and TRC105 Versus Axitinib Alone in Patients With Advanced or Metastatic Renal Cell Carcinoma
Phase: Phase II, Phase I
Type: Biomarker/Laboratory analysis, Treatment
Status: Active
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: 105RC101, NCT01806064
A Study of Axitinib in Patients With Advanced Angiosarcoma and Other Soft Tissue Sarcomas
Phase: Phase II
Type: Treatment
Status: Active
Age: 16 and over
Sponsor: Other
Protocol IDs: STH15195, 2008-006007-23, NCT01140737
Axitinib as Second-line Treatment for Advanced Hepatocellular Carcinoma
Phase: Phase II
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: Other
Protocol IDs: 201008013M, NCT01273662
Study of the Anti-Angiogenesis Agent Axitinib in Patients With Stage III Malignant Melanoma
Phase: Phase II
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: Other
Protocol IDs: UCI 10-55, 2011-8282, WS830279, NCT01321437
Nasopharyngeal Carcinoma (NPC) Axitinib
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Status: Active
Age: 18 and over
Sponsor: Other
Protocol IDs: NPC022, NCT01249547
Neoadjuvant Axitinib in Prostate Cancer
Phase: Phase II
Type: Biomarker/Laboratory analysis, Tissue collection/Repository, Treatment
Status: Active
Age: 18 and over
Sponsor: Other
Protocol IDs: 2011-0231, NCI-2011-02749, NCT01409200
Phase II Axitinib (AG-013736) in Elderly Glioblastoma Multiforme (GBM) Patients
Phase: Phase II
Type: Treatment
Status: Active
Age: Over 70
Sponsor: Other
Protocol IDs: UCCR-2, NCT01508117
A Randomized Phase II Clinical Trial on the Efficacy of Axitinib as a Monotherapy or in Combination With Lomustine for the Treatment of Patients With Recurrent Glioblastoma
Phase: Phase II
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: AxiGII, NCT01562197
A Phase II Study of Axitinib in Patients With Metastatic Renal Cell Cancer Unsuitable for Nephrectomy
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Status: Active
Age: 18 and over
Sponsor: Other
Protocol IDs: ICR-CTSU/2011/10033, NCT01693822
Study of Dalantercept and Axitinib in Patients With Advanced Renal Cell Carcinoma
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Status: Active
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: A041-04, ACE-041, NCT01727336
A Phase II Study of Axitinib in Metastatic Non-clear Cell Renal Cell Carcinoma Patients Previously Treated With Temsirolimus
Phase: Phase II
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: Other
Protocol IDs: H-1301-124-461, SNUH_Axitinib_NCCRCC, NCT01798446
Phase II Study of Axitinib (AG-013736) With Evaluation of the VEGF-pathway in Metastatic, Recurrent or Primary Unresectable Pheochromocytoma/Paraganglioma
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Status: Active
Age: 18 and over
Sponsor: NCI
Protocol IDs: 140001, 14-C-0001, NCT01967576
Study of Axitinib in Patients With Neurofibromatosis Type 2 and Progressive Vestibular Schwannomas
Phase: Phase II
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: Other
Protocol IDs: s14-00004, NCT02129647
CRLX101 in Combination With Bevacizumab for Metastatic Renal Cell Carcinoma (mRCC) Versus Standard of Care (SOC)
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Status: Active
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: CRLX101-208, NCT02187302
Phase II Study on Axitinib in Advanced Solitary Fibrous Tumor
Phase: Phase II
Type: Treatment
Status: Approved-not yet active
Age: Over 18
Sponsor: Other
Protocol IDs: SFT-AX2014, 2013-005596-40, NCT02261207
A Phase 1b Study Of Axitinib In Combination With Crizotinib In Patients With Advanced Solid Tumors
Phase: Phase I
Type: Biomarker/Laboratory analysis, Treatment
Status: Active
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: A4061068, 2015-001724-31, NCT01999972
A Dose Finding Study To Evaluate Safety, Drug Interaction, Tumor Markers Of Axitinib In Combination With MK-3475 In Adult Patients With Previously Untreated Advanced Renal Cell Cancer
Phase: Phase I
Type: Biomarker/Laboratory analysis, Treatment
Status: Active
Age: 18 to 95
Sponsor: Pharmaceutical / Industry
Protocol IDs: A4061079, NCT02133742
VEGF Receptor Tyrosine Kinase Inhibitor Axitinib in Children With Recurrent or Refractory Solid Tumors
Phase: Phase I
Type: Biomarker/Laboratory analysis, Treatment
Status: Active
Age: 1 to 17
Sponsor: Other
Protocol IDs: ADVL1315, NCT02164838
Prediction of Response to Kinase Inhibitors Based on Protein Phosphorylation Profiles in Tumor Tissue From Advanced Renal Cell Cancer Patients
Phase: No phase specified
Type: Biomarker/Laboratory analysis, Natural history/Epidemiology
Status: Active
Age: 18 and over
Sponsor: Other
Protocol IDs: 2012/109, NCT02071719
Start Over